177 related articles for article (PubMed ID: 37482124)
1. PEGylated Polymeric Nanoparticles Loaded with 2-Methoxyestradiol for the Treatment of Uterine Leiomyoma in a Patient-Derived Xenograft Mouse Model.
Enazy SA; Kirschen GW; Vincent K; Yang J; Saada J; Shah M; Oberhauser AF; Bujalowski PJ; Motamedi M; Salama SA; Kilic G; Rytting E; Borahay MA
J Pharm Sci; 2023 Sep; 112(9):2552-2560. PubMed ID: 37482124
[TBL] [Abstract][Full Text] [Related]
2. Liposomal 2-Methoxyestradiol Nanoparticles for Treatment of Uterine Leiomyoma in a Patient-Derived Xenograft Mouse Model.
Borahay MA; Vincent KL; Motamedi M; Tekedereli I; Salama SA; Ozpolat B; Kilic GS
Reprod Sci; 2021 Jan; 28(1):271-277. PubMed ID: 32632769
[TBL] [Abstract][Full Text] [Related]
3. Application of a Patient Derived Xenograft Model for Predicative Study of Uterine Fibroid Disease.
Fritsch M; Schmidt N; Gröticke I; Frisk AL; Keator CS; Koch M; Slayden OD
PLoS One; 2015; 10(11):e0142429. PubMed ID: 26588841
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin-loaded liposome nanoparticles treatment for uterine leiomyoma in a patient-derived xenograft mouse model: a pilot study.
El Sabeh M; Vincent KL; Afrin S; Motamedi M; Saada J; Yang J; Ozpolat B; Kilic GS; Borahay MA
J Obstet Gynaecol; 2022 Aug; 42(6):2139-2143. PubMed ID: 35166183
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a novel xenograft model for human uterine leiomyoma in immunodeficient mice.
Tsuiji K; Takeda T; Li B; Kondo A; Ito M; Yaegashi N
Tohoku J Exp Med; 2010 Sep; 222(1):55-61. PubMed ID: 20814179
[TBL] [Abstract][Full Text] [Related]
6. Halofuginone suppresses growth of human uterine leiomyoma cells in a mouse xenograft model.
Koohestani F; Qiang W; MacNeill AL; Druschitz SA; Serna VA; Adur M; Kurita T; Nowak RA
Hum Reprod; 2016 Jul; 31(7):1540-51. PubMed ID: 27130615
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine for uterine leiomyoma therapy.
Ali H; Kilic G; Vincent K; Motamedi M; Rytting E
Ther Deliv; 2013 Feb; 4(2):161-75. PubMed ID: 23343157
[TBL] [Abstract][Full Text] [Related]
8. Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study.
Borahay MA; Vincent K; Motamedi M; Sbrana E; Kilic GS; Al-Hendy A; Boehning D
Am J Obstet Gynecol; 2015 Aug; 213(2):196.e1-8. PubMed ID: 25840272
[TBL] [Abstract][Full Text] [Related]
9. Nonobese diabetic/severe combined immunodeficient murine xenograft model for human uterine leiomyoma.
Wang G; Ishikawa H; Sone K; Kobayashi T; Kim JJ; Kurita T; Shozu M
Fertil Steril; 2014 May; 101(5):1485-92. PubMed ID: 24636398
[TBL] [Abstract][Full Text] [Related]
10. Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth.
Ono M; Yin P; Navarro A; Moravek MB; Coon JS; Druschitz SA; Serna VA; Qiang W; Brooks DC; Malpani SS; Ma J; Ercan CM; Mittal N; Monsivais D; Dyson MT; Yemelyanov A; Maruyama T; Chakravarti D; Kim JJ; Kurita T; Gottardi CJ; Bulun SE
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17053-8. PubMed ID: 24082114
[TBL] [Abstract][Full Text] [Related]
11. Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation.
Hu S; Zhang Y
Int J Nanomedicine; 2010 Nov; 5():1039-48. PubMed ID: 21170352
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.
Commandeur AE; Styer AK; Teixeira JM
Hum Reprod Update; 2015; 21(5):593-615. PubMed ID: 26141720
[TBL] [Abstract][Full Text] [Related]
13. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants.
Desai KG; Mallery SR; Schwendeman SP
Eur J Pharm Biopharm; 2008 Sep; 70(1):187-98. PubMed ID: 18472254
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation.
Afrin S; El Sabeh M; Islam MS; Miyashita-Ishiwata M; Malik M; Catherino WH; Akimzhanov AM; Boehning D; Yang Q; Al-Hendy A; Segars JH; Borahay MA
Pharmacol Res; 2021 Oct; 172():105856. PubMed ID: 34461224
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a novel mouse xenograft model of human uterine leiomyoma.
Suzuki Y; Ii M; Saito T; Terai Y; Tabata Y; Ohmichi M; Asahi M
Sci Rep; 2018 Jun; 8(1):8872. PubMed ID: 29891843
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
17. Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model.
Chitphet K; Geary SM; Chan CHF; Simons AL; Weiner GJ; Salem AK
ACS Biomater Sci Eng; 2020 May; 6(5):2659-2667. PubMed ID: 33463284
[TBL] [Abstract][Full Text] [Related]
18. BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies.
Wagenfeld A; Bone W; Schwede W; Fritsch M; Fischer OM; Moeller C
Hum Reprod; 2013 Aug; 28(8):2253-64. PubMed ID: 23739217
[TBL] [Abstract][Full Text] [Related]
19. Preferential tumor accumulation and desirable interstitial penetration of poly(lactic-co-glycolic acid) nanoparticles with dual coating of chitosan oligosaccharide and polyethylene glycol-poly(D,L-lactic acid).
Wang G; Chen Y; Wang P; Wang Y; Hong H; Li Y; Qian J; Yuan Y; Yu B; Liu C
Acta Biomater; 2016 Jan; 29():248-260. PubMed ID: 26476340
[TBL] [Abstract][Full Text] [Related]
20. Polymeric nano-encapsulation of 5-fluorouracil enhances anti-cancer activity and ameliorates side effects in solid Ehrlich Carcinoma-bearing mice.
Haggag YA; Osman MA; El-Gizawy SA; Goda AE; Shamloula MM; Faheem AM; McCarron PA
Biomed Pharmacother; 2018 Sep; 105():215-224. PubMed ID: 29857301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
